Skip to content
← All treatment topics

TREATMENT READING

Cancer of Unknown Primary (CUP)

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

39 sections
  1. Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary
  2. Single-Site or Oligometastatic Disease Amenable to Surgery or Radiation Therapy
  3. Cervical Lymph Node(s) With Squamous Cell Histology (Head and Neck Paradigm)
  4. Inguinal Lymph Nodes With Squamous Cell Histology (Genitourinary or Anorectal Source)
  5. Axillary Lymph Node(s) With Adenocarcinoma Histology (Breast Paradigm)
  6. Bone Metastases if Blastic (Breast Paradigm for Women, Prostate Paradigm for Men)
  7. Elevated AFP and/or Beta-hCG (Germ Cell Paradigm)
  8. Peritoneal Carcinomatosis if Adenocarcinoma (Ovarian Paradigm)
  9. Targeted Therapy Defined by Molecular Markers or by Next-Generation Sequencing (Including PD-L1, HRD, MSI)
  10. Neuroendocrine Neoplasms
  11. Melanoma (Melanotic or Amelanotic) Occurring in a Single Lymph Node Site
  12. Treatment of Newly Diagnosed Unfavorable Cancer of Unknown Primary
  13. Treatment Options for Newly Diagnosed Unfavorable CUP
  14. Site-directed therapy based on molecular tissue of origin or molecular targeted therapy
  15. Immunological therapy
  16. Chemotherapy
  17. Follow-Up Treatment of Cancer of Unknown Primary in Remission
  18. The information that is known about the cancer is used to plan treatment.
  19. Treatment Option Overview
  20. Key Points
  21. There are different types of treatment for patients with carcinoma of unknown primary (CUP).
  22. Four types of standard treatment are used:
  23. Surgery
  24. Radiation therapy
  25. Chemotherapy
  26. Hormone therapy
  27. New types of treatment are being tested in clinical trials.
  28. Treatment for carcinoma of unknown primary may cause side effects.
  29. Patients may want to think about taking part in a clinical trial.
  30. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  31. Treatment of Newly Diagnosed Carcinoma of Unknown Primary
  32. Cervical (Neck) Lymph Nodes
  33. Poorly Differentiated Carcinomas
  34. Women with Peritoneal Cancer
  35. Isolated Axillary Lymph Node Metastasis
  36. Inguinal Lymph Node Metastasis
  37. Melanoma in a Single Lymph Node Area
  38. Multiple Involvement
  39. Treatment of Recurrent Carcinoma of Unknown Primary

Health professional

Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Twenty percent of patients with cancer of unknown primary (CUP) have favorable CUP. Favorable CUP is defined by the following characteristics:

Single-site or oligometastatic disease amenable to surgery or radiation therapy.

Sources: Single-site or oligometastatic disease amenable to surgery or radiation therapy

Cervical lymph node(s) with squamous cell histology (head and neck paradigm).

Sources: Cervical lymph node(s) with squamous cell histology (head and neck paradigm)

Inguinal lymph nodes with squamous cell histology (genitourinary or anorectal source).

Sources: Inguinal lymph nodes with squamous cell histology (genitourinary or anorectal source)

Axillary lymph node(s) with adenocarcinoma histology (breast paradigm).

Sources: Axillary lymph node(s) with adenocarcinoma histology (breast paradigm)

Bone metastases if blastic (breast paradigm for women, prostate paradigm for men).

Sources: Bone metastases if blastic (breast paradigm for women, prostate paradigm for men)

Elevated alpha-fetoprotein (AFP) and/or beta-human chorionic gonadotropin (beta-hCG) (germ cell paradigm).

Sources: Elevated alpha-fetoprotein (AFP) and/or beta-human chorionic gonadotropin (beta-hCG) (germ cell paradigm)

Peritoneal carcinomatosis if adenocarcinoma (ovarian paradigm).

Sources: Peritoneal carcinomatosis if adenocarcinoma (ovarian paradigm)

Targeted therapy defined by molecular markers or by next-generation sequencing (including PD-L1, homologous recombination repair deficiency [HRD], microsatellite instability [MSI]).

Sources: Targeted therapy defined by molecular markers or by next-generation sequencing (including PD-L1, homologous recombination repair deficiency [HRD], microsatellite instability [MSI])

Neuroendocrine neoplasms.

Sources: Neuroendocrine neoplasms

Melanoma (melanotic or amelanotic) occurring in a single lymph node site.

Sources: Melanoma (melanotic or amelanotic) occurring in a single lymph node site

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Single-Site or Oligometastatic Disease Amenable to Surgery or Radiation Therapy

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

According to a consensus paper, when a single site of metastasis can be confirmed by positron emission tomography–computed tomography (PET-CT) scan and magnetic resonance imaging (MRI) of the brain, local treatment with surgery or radiation therapy is an option. Local treatment has resulted in anecdotal cure in a few patients and several months to years of anecdotal relapse-free survival in a few patients.[1][Level of evidence C3] Anecdotal reports also support localized therapy for patients with fewer than five metastases, or even re-treatment with radiation therapy or surgery for patients with localized recurrence.[2][Level of evidence C3] A patient staged with CUP and a single brain metastasis may also do well with radiation therapy with or without surgery, as was reported in a prospective study of 33 patients.[3,4][Level of evidence C3]

Sources: 1 · Level of evidence C3 · 2 · Level of evidence C3 · 3 · 4 · Level of evidence C3

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Cervical Lymph Node(s) With Squamous Cell Histology (Head and Neck Paradigm)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

PET-CT, MRI, and pan-endoscopy for biopsies and bilateral tonsillectomies are performed when squamous cell carcinoma is identified in cervical lymph nodes (not supraclavicular) in patients with CUP.[5]

Sources: 5

Transoral robotic surgery may replace pan-endoscopy in the search for a primary site in the head and neck region.[6] Pathological studies should include testing for p16 expression to assess human papillomavirus status, Epstein-Barr virus status, and PD-L1 expression.[7]

Sources: 6 · 7

For more information, see Metastatic Squamous Neck Cancer with Occult Primary Treatment.

Sources: Metastatic Squamous Neck Cancer with Occult Primary Treatment

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Inguinal Lymph Nodes With Squamous Cell Histology (Genitourinary or Anorectal Source)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Squamous cell carcinoma in an inguinal or iliac site is usually associated with a genital or anorectal primary. Examinations should focus on the vulva, vagina, and cervix in women, and the penis in men. In both sexes, the anorectal area should be examined, and any suspicious areas should be biopsied. Anecdotal cures have been reported in a few cases of isolated inguinal or iliac sites with an occult primary after staging studies.[8]

Sources: 8

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Axillary Lymph Node(s) With Adenocarcinoma Histology (Breast Paradigm)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Less than 1% of female patients present with histological breast cancer in an axillary lymph node with an occult primary even after MRI of the breast.[9] Initial pathological studies should include estrogen-receptor, progesterone-receptor, and human epidermal growth factor (HER2) status, with further molecular and genetic studies done subsequently. Surgery, radiation therapy, neoadjuvant or adjuvant chemotherapy, and/or hormonal therapy are given according to guidelines for conventional breast cancer.[10-13]

Sources: 9 · 10 · 13

For more information, see Breast Cancer Treatment.

Sources: Breast Cancer Treatment

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Bone Metastases if Blastic (Breast Paradigm for Women, Prostate Paradigm for Men)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

The presence of blastic bone metastases or mixed blastic/lytic lesions will usually suggest breast cancer in women and prostate cancer in men. Diagnostic procedures and therapeutic options should proceed in these directions.

For more information, see Breast Cancer Treatment or Prostate Cancer Treatment.

Sources: Breast Cancer Treatment · Prostate Cancer Treatment

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Elevated AFP and/or Beta-hCG (Germ Cell Paradigm)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

The presence of elevated serum or tissue levels of AFP and/or beta-hCG suggests testicular cancer or extragonadal germ cell tumor in males. Men younger than 50 years with mediastinal adenopathy and pulmonary metastases have immunohistochemical evidence of AFP and/or beta-hCG in the extragonadal presentation. Diagnostic procedures and therapeutic options should proceed in these directions.

For more information, see Testicular Cancer Treatment and Extragonadal Germ Cell Tumors Treatment.

Sources: Testicular Cancer Treatment · Extragonadal Germ Cell Tumors Treatment

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Peritoneal Carcinomatosis if Adenocarcinoma (Ovarian Paradigm)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Women with peritoneal carcinomatosis of an undifferentiated adenocarcinoma or serous histology in the absence of an ovarian, fallopian tube, or uterine primary site should undergo diagnostic testing and a therapeutic approach for ovarian cancer.[14] This is considered a primary peritoneal serous carcinoma.

Sources: 14

For more information, see Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment.

Sources: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Targeted Therapy Defined by Molecular Markers or by Next-Generation Sequencing (Including PD-L1, HRD, MSI)

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Clinical, pathological, and molecular genetic tests have two goals. The first is to identify tumors that are responsive to available therapies. The second is to identify novel targeted therapies that might be applicable to the particular genetic profile. The U.S. Food and Drug Administration has approved some novel targeted therapies when a molecular target is identified in a cancer, regardless of primary site or when no primary site is evident. Examples include tumors with the following actionable targets:[15-22]

Sources: 15 · 22

High tumor mutational burden.

Elevated PD-1 or PD-L1 expression.

HER2 expression.

Pathogenic variants in NTRK, RET, or EGFR.

BRAF V600E pathogenic variant.

ROS1 gene fusion.

MET amplification.

HRD/MSI.

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Neuroendocrine Neoplasms

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Neuroendocrine neoplasms are classified as well-differentiated neuroendocrine tumors (NETs) and slow progression neuroendocrine carcinomas (NEC). Well-differentiated NETs exhibit relatively indolent behavior. Slow progression NECs may exhibit highly aggressive behavior, with a rapid metastatic spread that is clinically indistinguishable from pancreatic adenocarcinoma or small cell lung cancer. The Ki-67 proliferative index rate is used to subclassify well-differentiated NETs into low, intermediate, and high-grade, while NECs are by default high-grade and poorly differentiated and divided into small- and large-cell NEC.

NETs of unknown primary origin may derive from the small bowel, pancreas, appendix, colon, rectum, or ovary.[23,24] Somatostatin receptor PET-CT scans are highly effective at identifying primary sites and metastatic sites for well-differentiated NETs, while fluorine F 18-fludeoxyglucose–PET is more appropriate for NEC.[25-27]

Sources: 23 · 24 · 25 · 27

For more information, see Gastrointestinal Neuroendocrine Tumors Treatment.

Sources: Gastrointestinal Neuroendocrine Tumors Treatment

Merkel cell carcinoma is a rare, aggressive, cutaneous malignancy of neuroendocrine origin, usually with primary lesions in the head and neck or in the extremities. However, it may present in the lymph nodes only, with no evident primary site.[28]

Sources: 28

For more information, see Merkel Cell Carcinoma Treatment.

Sources: Merkel Cell Carcinoma Treatment

Health professional · Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

Melanoma (Melanotic or Amelanotic) Occurring in a Single Lymph Node Site

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Approximately 5% of patients with malignant melanoma will present without a documented primary site. Diagnostic studies and therapeutic options should proceed with the paradigm of malignant melanoma.[29]

Sources: 29

For more information, see Melanoma Treatment.

Sources: Melanoma Treatment

Health professional

Treatment of Newly Diagnosed Unfavorable Cancer of Unknown Primary

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Most patients with newly diagnosed cancer of unknown primary (CUP) are considered to have an unfavorable prognosis.

Health professional · Treatment of Newly Diagnosed Unfavorable Cancer of Unknown Primary

Treatment Options for Newly Diagnosed Unfavorable CUP

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Treatment options for newly diagnosed unfavorable CUP include the following:

Site-directed therapy based on molecular tissue of origin/molecular targeted therapy.

Sources: Site-directed therapy based on molecular tissue of origin/molecular targeted therapy

Immunological therapy.

Sources: Immunological therapy

Chemotherapy.

Sources: Chemotherapy

Health professional · Treatment of Newly Diagnosed Unfavorable Cancer of Unknown Primary / Treatment Options for Newly Diagnosed Unfavorable CUP

Site-directed therapy based on molecular tissue of origin or molecular targeted therapy

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Clinical, pathological, and molecular genetic tests have two goals. The first is to identify tumors that are responsive to available therapies. The second is to identify novel targeted therapies that might be applicable to the particular genetic profile. The U.S. Food and Drug Administration (FDA) has approved some novel targeted therapies when a molecular target is identified in a cancer, regardless of primary site or when no primary site is evident. Examples include tumors with the following actionable targets:[1-8]

Sources: 1 · 8

High tumor mutational burden (TMB-H).

Elevated PD-1 or PD-L1 expression.

HER2 expression.

Pathogenic variants in NTRK, RET, or EGFR.

BRAF V600E pathogenic variant.

ROS1 gene fusion.

MET amplification.

Homologous recombination repair deficiency/microsatellite instability (MSI).

Health professional · Treatment of Newly Diagnosed Unfavorable Cancer of Unknown Primary / Treatment Options for Newly Diagnosed Unfavorable CUP

Immunological therapy

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Immunological therapy using checkpoint inhibitors such as nivolumab has been given to a general population with unfavorable CUP, resulting in a 22% overall response rate.[8] Better response rates can be seen when checkpoint inhibitors are given to patients with tumors expressing high levels of MSI (MSI-H) or deficient mismatch repair (dMMR).[7] Patients with TMB-H disease, defined as at least 7.75 mutations [8] or 10 mutations [9] per megabase, also have higher response rates to immunotherapy.[6] The FDA has approved pembrolizumab in a tumor-agnostic situation (which includes CUP) for tumors with MSI-H, dMMR, or TMB-H.[7] High PD-L1 expression also correlates with higher response rates in patients who receive immunotherapy.[8] Further trials for patients with CUP are required to assess when to give checkpoint inhibitors and to define optimal cutoffs (1% to 50%) and scoring systems (cancer cell tumor proportion score vs. cancer-plus-surrounding cell combined positive score) to guide treatment.[10]

Sources: 8 · 7 · 8 · 9 · 6 · 7 · 8 · 10

Health professional · Treatment of Newly Diagnosed Unfavorable Cancer of Unknown Primary / Treatment Options for Newly Diagnosed Unfavorable CUP

Chemotherapy

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

Patients with unfavorable CUP who are not candidates for molecular targeted therapy or immunotherapy are candidates for clinical trials. Cytotoxic chemotherapy can be a palliative therapy, but the choice of drugs has been based on a few small clinical studies, with no randomized trials establishing their benefit over best supportive care.[10] Several randomized prospective studies demonstrate that platinum-based doublet chemotherapy combined with a taxane or gemcitabine is equivalent to other chemotherapy in response rate and progression-free survival.[11-14][Level of evidence B1] Although most patients in these trials had adenocarcinoma or poorly differentiated carcinoma, patients with poorly differentiated squamous cell carcinoma were included.

Sources: 10 · 11 · 14 · Level of evidence B1

Palliative care and hospice are options for patients with a poor performance status and relapsing disease.

Health professional

Follow-Up Treatment of Cancer of Unknown Primary in Remission

Source: Cancer of Unknown Primary (CUP) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 7, 2025. Captured 2026-09-09.

The use of follow-up studies including computed tomography or magnetic resonance imaging, is extrapolated from paradigms of other related malignancies with known primary sites. No prospective trials evaluating clinical surveillance have been conducted for patients with cancer of unknown primary.

For patients · Stages of Carcinoma of Unknown Primary

The information that is known about the cancer is used to plan treatment.

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Doctors use the following types of information to plan treatment:

The place in the body where the cancer is found, such as the peritoneum or the cervical (neck), axillary (armpit), or inguinal (groin) lymph nodes.

Sources: peritoneum · cervical · axillary · groin · lymph nodes

The type of cancer cell, such as melanoma.

Sources: cell · melanoma

Whether the cancer cell is poorly differentiated (looks very different from normal cells when viewed under a microscope).

Sources: differentiated · microscope

The signs and symptoms caused by the cancer.

Sources: signs · symptoms

The results of tests and procedures.

Whether the cancer is newly diagnosed or has recurred (come back).

Sources: diagnosed · recurred

For patients

Treatment Option Overview

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

There are different types of treatment for patients with carcinoma of unknown primary (CUP).

Four types of standard treatment are used:

Four types of standard treatment are used:

Surgery

Radiation therapy

Chemotherapy

Hormone therapy

New types of treatment are being tested in clinical trials.

Treatment for carcinoma of unknown primary may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

For patients · Treatment Option Overview

There are different types of treatment for patients with carcinoma of unknown primary (CUP).

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Different types of treatment are available for patients with CUP. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: CUP · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

Four types of standard treatment are used:

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For patients · Treatment Option Overview / Four types of standard treatment are used:

Surgery

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Surgery is a common treatment for CUP. A doctor may remove the cancer and some of the healthy tissue around it.

Sources: Surgery · tissue

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · radiation therapy · cells · adjuvant therapy

For patients · Treatment Option Overview / Four types of standard treatment are used:

Radiation therapy

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:

Sources: x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of radiation therapy may include the following:

Sources: External radiation therapy

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of radiation therapy may include the following:

Intensity-modulated radiation therapy (IMRT): IMRT is a type of 3-dimensional (3-D) radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles. This type of external radiation therapy causes less damage to nearby healthy tissue and is less likely to cause dry mouth, trouble swallowing, and damage to the skin.

Sources: Intensity-modulated radiation therapy · 3-dimensional · tumor

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat carcinoma of unknown primary.

Sources: stage

For patients · Treatment Option Overview / Four types of standard treatment are used:

Chemotherapy

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is the use of two or more anticancer drugs.

Sources: drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · abdomen · regional chemotherapy · Combination chemotherapy

For patients · Treatment Option Overview / Four types of standard treatment are used:

Hormone therapy

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show that the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy are used to reduce the production of hormones or block them from working.

Sources: Hormone therapy · hormones · glands · receptors

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for carcinoma of unknown primary may cause side effects.

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients

Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Cervical (Neck) Lymph Nodes

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Cancer found in cervical (neck) lymph nodes may have spread from a tumor in the head or neck. Treatment of cervical lymph node carcinoma of unknown primary (CUP) may include the following:

Sources: Cancer · cervical · lymph nodes · tumor · carcinoma of unknown primary

Surgery to remove the tonsils.

Sources: Surgery · tonsils

Radiation therapy alone. Intensity-modulated radiation therapy (IMRT) may be used.

Sources: Radiation therapy · Intensity-modulated radiation therapy

Radiation therapy followed by surgery to remove the lymph nodes.

Surgery to remove the lymph nodes, with or without radiation therapy.

A clinical trial of new types of treatment.

Sources: clinical trial

See the PDQ summary on Metastatic Squamous Neck Cancer with Occult Primary Treatment for more information.

Sources: PDQ · Metastatic Squamous Neck Cancer with Occult Primary Treatment

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Poorly Differentiated Carcinomas

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Cancer cells that are poorly differentiated look very different from normal cells. The type of cell they came from is not known. Treatment of poorly differentiated carcinoma of unknown primary, including tumors in the neuroendocrine system (the part of the brain that controls hormone-producing glands throughout the body) may include the following:

Sources: Cancer · cells · differentiated · carcinoma of unknown primary · tumors · neuroendocrine · hormone · glands

Combination chemotherapy.

Sources: Combination chemotherapy

A clinical trial of new types of treatment.

Sources: clinical trial

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Women with Peritoneal Cancer

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment for women who have peritoneal (lining of the abdomen) carcinoma of unknown primary may be the same as for ovarian cancer. Treatment may include the following:

Sources: peritoneal · abdomen · carcinoma of unknown primary · ovarian cancer

Chemotherapy.

Sources: Chemotherapy

A clinical trial of new types of treatment.

Sources: clinical trial

See the PDQ summary on Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment for more information.

Sources: PDQ · Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Isolated Axillary Lymph Node Metastasis

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Cancer found only in the axillary (armpit) lymph nodes may have spread from a tumor in the breast.

Sources: Cancer · axillary (armpit) lymph nodes · tumor · breast

Treatment of axillary lymph node metastasis is usually:

Sources: metastasis

Surgery to remove the lymph nodes.

Sources: Surgery

Treatment also may include one or more of the following:

Surgery to remove the breast.

Radiation therapy to the breast.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

A clinical trial of new types of treatment.

Sources: clinical trial

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Inguinal Lymph Node Metastasis

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Cancer found only in the inguinal (groin) lymph nodes most likely began in the genital, anal, or rectal area. Treatment of inguinal lymph node metastasis may include the following:

Sources: Cancer · groin · lymph nodes · genital · anal · rectal · metastasis

Surgery to remove the cancer and/or lymph nodes in the groin.

Sources: Surgery

Surgery to remove the cancer and/or lymph nodes in the groin, followed by radiation therapy or chemotherapy.

Sources: radiation therapy · chemotherapy

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Melanoma in a Single Lymph Node Area

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of melanoma that is found only in a single lymph node area is usually:

Sources: melanoma · lymph node

Surgery to remove the lymph nodes.

Sources: Surgery

See PDQ summary on Melanoma Treatment for more information.

Sources: PDQ · Melanoma Treatment

For patients · Treatment of Newly Diagnosed Carcinoma of Unknown Primary

Multiple Involvement

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

There is no standard treatment for carcinoma of unknown primary that is found in several different areas of the body. Treatment may include the following:

Sources: standard treatment · carcinoma of unknown primary

Hormone therapy.

Sources: Hormone therapy

Internal radiation therapy.

Sources: Internal radiation therapy

Chemotherapy with one or more anticancer drugs.

Sources: Chemotherapy · drugs

A clinical trial.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Carcinoma of Unknown Primary

Source: Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 17, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment for recurrent carcinoma of unknown primary is usually within a clinical trial. Treatment depends on the following:

Sources: recurrent · carcinoma of unknown primary · clinical trial

The type of cancer.

Sources: cancer

How the cancer was treated before.

Where the cancer has come back in the body.

The condition and wishes of the patient.

Sources: condition

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Disease and treatment settings

Cancer of Unknown Primary (CUP)

Disease and treatment setting

Cancer of Unknown Primary (CUP)

Cancer of Unknown Primary (CUP)

Disease and treatment setting

Treatment of Newly Diagnosed Favorable Cancer of Unknown Primary

recurrent Cancer of Unknown Primary (CUP)

Disease and treatment setting

Treatment of Recurrent Carcinoma of Unknown Primary